An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423

Hepatocellular Carcinoma Clinical Trial

Official title:

An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01316679
• Other study ID #: Urinary Biomarkers 101423
• Status: Completed
• Phase: N/A
• First received: March 15, 2011
• Last updated: April 10, 2017
• Start date: March 2011
• Est. completion date: January 2013

Study information

• Verified date: April 2017
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Ability and willingness to provide written informed consent

• Must be between 18-90 years of age at the time of consent

• Ability to provide urine specimen at protocol-defined timepoints

• Must have treatment interventions planned that are directly related to liver disease (excluding those assigned to group 3-Controls)

Exclusion Criteria:

• Suspected inability, e.g. unwillingness to comply with study procedures or unwillingness to provide written consent

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Liver Disease
• Liver Diseases

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center